Ava Risk Group (ASX:AVA) Secures A$1.1 Million Contract with Honeywell for Abu Dhabi Oil Field
Ava Risk Group (ASX:AVA) secures a A$1.1 million contract with Honeywell to deploy its sensing technology in Abu Dhabi’s oil and gas field.
Tamboran Resources Corporation (ASX:TBN) Announces 3Q FY25 Results
Tamboran Resources Corporation (ASX:TBN) announces 3Q FY25 results, highlighting successful well completions and financial milestones.
Bass Oil Limited (ASX:BAS) Announces Rights Issue and Strategic Acquisitions
Bass Oil Limited (ASX:BAS) announces a rights issue and strategic acquisitions to accelerate growth and unlock long-term value for investors.
Euro Manganese (ASX:EMN) Completes Oversubscribed Security Purchase Plan
Euro Manganese (ASX:EMN) completes its oversubscribed Security Purchase Plan, raising A$1.5 million to advance the Chvaletice Manganese Project.
Dropsuite Limited (ASX:DSE) Announces Federal Court Approval of Acquisition Scheme
Dropsuite Limited (ASX:DSE) secures Federal Court approval for its acquisition by NinjaOne, outlining scheme considerations and key timelines.
Bass Oil Limited (ASX:BAS) Acquires Vanessa Gas Field and Launches $3.1M Capital Raise
Bass Oil Limited (ASX:BAS) acquires the Vanessa gas field and launches a $3.1 million capital raise to support growth initiatives.
Epsilon Healthcare Limited (ASX:EPN) Announces Issue of $1M Loan Notes
Epsilon Healthcare Limited (ASX:EPN) issues loan notes to raise $1 million for operational expansion and diversification.
Babylon Pump & Power Limited (ASX:BPP) Acquires Matrix Hydro Services and Launches ANREO
Babylon Pump & Power (ASX:BPP) acquires Matrix Hydro Services and launches a $3.5m ANREO to enhance its water management capabilities.
Mayne Pharma (ASX:MYX) Receives Court Approval for Acquisition Scheme
Mayne Pharma (ASX:MYX) receives Supreme Court approval for Cosette Pharmaceuticals’ acquisition scheme, leading to an upcoming shareholder vote.
Mesoblast (ASX:MSB) Receives 7-Year FDA Orphan Drug Approval for Ryoncil™
Mesoblast (ASX:MSB) secures 7-year FDA orphan-drug exclusivity for Ryoncil™ in treating pediatric SR-aGvHD, strengthening its IP protection.